EGFR and neoplasm: Compared to tumors harboring wild-type EGFR, EGFR-driven NSCLC tumors exhibit low tumor immunogenicity, including reduced TMB, fewer neoantigens, impaired T cell clonality, and lower PD-L1 expression.